当前位置: 首页 > 期刊 > 《中国当代医药》 > 2019年第22期
编号:13414374
双亚苄基哌啶与蛋白酶体抑制剂下调ADRM1表达诱导HL60细胞凋亡(4)
http://www.100md.com 2019年8月5日 《中国当代医药》 2019年第22期
     [15]Anchoori RK,Karanam B,Peng S,et al.A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer[J].Cancer Cell,2013,24:791-805.

    [16]Lu X,Zhou C,Li R,et al.Long noncoding RNA AFAP1-AS1 promoted tumor growth and invasion in cholangiocarcinoma[J].Cell Physiol Biochem,2017,42:222-230.

    [17]Song Y,Park PMC,Wu L,et al.Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma[J].Leukemia,2019[Epub ahead of print]

    [18]Anchoori RK,Jiang R,Peng S,et al.Covalent Rpn13-binding inhibitors for the treatment of ovarian cancer[J].ACS Omega,2018,3(9):11 917-11 929.

    [19]Yu GY,Wang X,Zheng SS,et al.RA190,a proteasome subunit ADRM1 inhibitor,suppresses intrahepatic cholangiocarcinoma by inducing NF-κB-mediated cell apoptosis[J].Cell Physiol Biochem,2018,47(3):1152-1166.

    [20]Lu X,Nowicka U,Sridharan V,et al.Structure of the Rpn13-Rpn2 complex provides insights for Rpn13 and Uch37 as anticancer targets[J].Nat Commun,2017,8:15 540.

    (收稿日期:2019-04-24 本文編辑:许俊琴), http://www.100md.com(郑晓辉 王玉孝 隋华秀)
上一页1 2 3 4